Medtronic Launches New Diabetes Software Following FDA Approval

Shares

Medtronic announced the market launch of CareLink®Pro 3.0 Therapy Management Software, the first software program to offer advanced decision support to healthcare professionals managing diabetes. This announcement was made following the Food and Drug Administration approval of the software for diabetes management support.

The software analyzes data from a patient’s insulin pump, continuous glucose monitoring (CGM) device, and blood glucose meter to identify the most important patient information in one easy-to-use dashboard.  In addition, the software offers therapy considerations that clinicians can use as a starting point to discuss therapy changes with their patients to help improve glucose control. The Dashboard provides a snapshot of the patient’s key insulin delivery and glucose information on one page.  In addition, it pinpoints the exact times the patient experienced a low (hypoglycemic) or high (hyperglycemic) glucose pattern and prioritizes these patterns so that clinicians know which times of day are the biggest challenges for their patients.The new Episode Summary highlights key events that occur prior to  hypoglycemic and hyperglycemic episodes, providing clinicians with quick insights on potential areas that may need to be addressed.  Furthermore, the Episode Summary offers therapy considerations so that clinicians can make the most informed treatment decisions possible. By reducing the amount of time it takes to interpret patient data, clinicians may have more time to spend with patients fine tuning and making adjustments to therapy and behavior.

CareLink is an integral part of the MiniMed Paradigm® REAL-Time Revel™ System, which is the only FDA approved integrated system that combines an insulin pump with CGM. The recent STAR 3 trial demonstrated that patients in all age groups (adults, teens, and children) using the Medtronic integrated system achieved a statistically significant reduction in A1c at three months, which was sustained over the course of one year. A1c is a measurement of glucose control over a two-to-three-month period.

Leave a Reply

avatar
3000
  Subscribe  
Notify of
Copyright © 2009-2017 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.